AR014456A1 - Derivados de sulfonamida como inhibidores de la resorcion osea y como inhibidores de la adhesion celular, un proceso para su preparacion ycomposicion farmaceutica que los contienen - Google Patents
Derivados de sulfonamida como inhibidores de la resorcion osea y como inhibidores de la adhesion celular, un proceso para su preparacion ycomposicion farmaceutica que los contienenInfo
- Publication number
- AR014456A1 AR014456A1 ARP990100244A ARP990100244A AR014456A1 AR 014456 A1 AR014456 A1 AR 014456A1 AR P990100244 A ARP990100244 A AR P990100244A AR P990100244 A ARP990100244 A AR P990100244A AR 014456 A1 AR014456 A1 AR 014456A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- inhibitors
- aryl
- substituted
- heteroaryl
- Prior art date
Links
- 229940124530 sulfonamide Drugs 0.000 title abstract 2
- 150000003456 sulfonamides Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 2
- 230000001413 cellular effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- -1 cyano, hydroxyl Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/16—Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1248998A | 1998-01-23 | 1998-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR014456A1 true AR014456A1 (es) | 2001-02-28 |
Family
ID=21755208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990100244A AR014456A1 (es) | 1998-01-23 | 1999-01-29 | Derivados de sulfonamida como inhibidores de la resorcion osea y como inhibidores de la adhesion celular, un proceso para su preparacion ycomposicion farmaceutica que los contienen |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1049677A1 (enExample) |
| JP (1) | JP2002501054A (enExample) |
| KR (1) | KR20010034319A (enExample) |
| CN (1) | CN1177832C (enExample) |
| AP (1) | AP1269A (enExample) |
| AR (1) | AR014456A1 (enExample) |
| AU (1) | AU752882B2 (enExample) |
| BG (1) | BG104630A (enExample) |
| BR (1) | BR9907735A (enExample) |
| CA (1) | CA2318221A1 (enExample) |
| EA (1) | EA003102B1 (enExample) |
| HR (1) | HRP20000493A2 (enExample) |
| HU (1) | HUP0100520A3 (enExample) |
| ID (1) | ID26219A (enExample) |
| IL (1) | IL137423A0 (enExample) |
| NO (1) | NO318795B1 (enExample) |
| NZ (1) | NZ505613A (enExample) |
| PL (1) | PL341871A1 (enExample) |
| SK (1) | SK10632000A3 (enExample) |
| TR (1) | TR200002160T2 (enExample) |
| TW (1) | TWI247742B (enExample) |
| UA (1) | UA63990C2 (enExample) |
| WO (1) | WO1999037621A1 (enExample) |
| YU (1) | YU47200A (enExample) |
| ZA (1) | ZA99476B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2338275A1 (en) * | 1998-07-29 | 2000-02-10 | Merck & Co., Inc. | Integrin receptor antagonists |
| EP1028114A1 (en) | 1999-02-13 | 2000-08-16 | Aventis Pharma Deutschland GmbH | Novel guanidine derivatives as inhibitors of cell adhesion |
| EP1065207A1 (en) * | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them |
| EP1065208A1 (en) * | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Substituted purine derivatives as inhibitors of cell adhesion |
| EP1070707A1 (en) * | 1999-07-21 | 2001-01-24 | Aventis Pharma Deutschland GmbH | 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor |
| US6849639B2 (en) | 1999-12-14 | 2005-02-01 | Amgen Inc. | Integrin inhibitors and their methods of use |
| EP1108721A1 (en) * | 1999-12-15 | 2001-06-20 | Aventis Pharma Deutschland GmbH | Thienylalanine derivatives as inhibitors of cell adhesion |
| WO2001047874A1 (en) * | 1999-12-24 | 2001-07-05 | Smithkline Beecham P.L.C. | (hetero)bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives |
| FR2808798A1 (fr) * | 2000-05-09 | 2001-11-16 | Hoechst Marion Roussel Inc | Nouveaux derives antagonistes du recepteur de la vitronectine |
| FR2847254B1 (fr) | 2002-11-19 | 2005-01-28 | Aventis Pharma Sa | Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant |
| WO2005090329A1 (en) * | 2004-03-24 | 2005-09-29 | Jerini Ag | New compounds for the inhibition of angiogenesis and use of thereof |
| FR2870541B1 (fr) | 2004-05-18 | 2006-07-14 | Proskelia Sas | Derives de pyrimidines antigonistes du recepteur de la vitronectine |
| GB0412553D0 (en) * | 2004-06-04 | 2004-07-07 | Univ Aberdeen | Therapeutic agents for the treatment of bone conditions |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| FR2873585B1 (fr) * | 2004-07-27 | 2006-11-17 | Aventis Pharma Sa | Nouvelles formulations galeniques de principes actifs |
| GB0705400D0 (en) | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
| GB0817208D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
| GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
| CA2950390C (en) | 2014-05-30 | 2020-09-22 | Pfizer Inc. | Carbonitrile derivatives as selective androgen receptor modulators |
| CA2970578C (en) | 2014-12-17 | 2024-01-02 | Pimco 2664 Limited | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE227567T1 (de) * | 1994-05-27 | 2002-11-15 | Merck & Co Inc | Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption |
| JP3895792B2 (ja) * | 1995-12-08 | 2007-03-22 | プロスケリア・エス・ア・エス | 骨形成促進剤 |
-
1999
- 1999-01-16 SK SK1063-2000A patent/SK10632000A3/sk unknown
- 1999-01-16 IL IL13742399A patent/IL137423A0/xx unknown
- 1999-01-16 AU AU25181/99A patent/AU752882B2/en not_active Ceased
- 1999-01-16 HR HR20000493A patent/HRP20000493A2/hr not_active Application Discontinuation
- 1999-01-16 PL PL99341871A patent/PL341871A1/xx unknown
- 1999-01-16 CN CNB998040894A patent/CN1177832C/zh not_active Expired - Fee Related
- 1999-01-16 JP JP2000528545A patent/JP2002501054A/ja not_active Abandoned
- 1999-01-16 UA UA2000084983A patent/UA63990C2/uk unknown
- 1999-01-16 AP APAP/P/2000/001863A patent/AP1269A/en active
- 1999-01-16 NZ NZ505613A patent/NZ505613A/xx unknown
- 1999-01-16 ID IDW20001407A patent/ID26219A/id unknown
- 1999-01-16 YU YU47200A patent/YU47200A/sh unknown
- 1999-01-16 EA EA200000785A patent/EA003102B1/ru not_active IP Right Cessation
- 1999-01-16 BR BR9907735-3A patent/BR9907735A/pt not_active IP Right Cessation
- 1999-01-16 CA CA002318221A patent/CA2318221A1/en not_active Abandoned
- 1999-01-16 HU HU0100520A patent/HUP0100520A3/hu unknown
- 1999-01-16 TR TR2000/02160T patent/TR200002160T2/xx unknown
- 1999-01-16 WO PCT/EP1999/000242 patent/WO1999037621A1/en not_active Ceased
- 1999-01-16 EP EP99904789A patent/EP1049677A1/en not_active Withdrawn
- 1999-01-16 KR KR1020007008041A patent/KR20010034319A/ko not_active Abandoned
- 1999-01-22 ZA ZA9900476A patent/ZA99476B/xx unknown
- 1999-01-29 AR ARP990100244A patent/AR014456A1/es not_active Application Discontinuation
- 1999-04-30 TW TW088100862A patent/TWI247742B/zh active
-
2000
- 2000-07-21 NO NO20003765A patent/NO318795B1/no unknown
- 2000-07-21 BG BG104630A patent/BG104630A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1177832C (zh) | 2004-12-01 |
| KR20010034319A (ko) | 2001-04-25 |
| AP1269A (en) | 2004-04-03 |
| CN1293662A (zh) | 2001-05-02 |
| BG104630A (en) | 2001-04-30 |
| CA2318221A1 (en) | 1999-07-29 |
| TWI247742B (en) | 2006-01-21 |
| HUP0100520A3 (en) | 2002-11-28 |
| UA63990C2 (uk) | 2004-02-16 |
| NZ505613A (en) | 2002-11-26 |
| ID26219A (id) | 2000-12-07 |
| HUP0100520A1 (hu) | 2001-07-30 |
| EP1049677A1 (en) | 2000-11-08 |
| EA200000785A1 (ru) | 2001-02-26 |
| EA003102B1 (ru) | 2002-12-26 |
| AP2000001863A0 (en) | 2000-09-30 |
| WO1999037621A1 (en) | 1999-07-29 |
| AU752882B2 (en) | 2002-10-03 |
| TR200002160T2 (tr) | 2001-07-23 |
| YU47200A (sh) | 2002-11-15 |
| BR9907735A (pt) | 2000-10-17 |
| SK10632000A3 (sk) | 2001-02-12 |
| NO20003765L (no) | 2000-09-25 |
| AU2518199A (en) | 1999-08-09 |
| IL137423A0 (en) | 2001-07-24 |
| PL341871A1 (en) | 2001-05-07 |
| NO318795B1 (no) | 2005-05-09 |
| ZA99476B (en) | 1999-08-05 |
| JP2002501054A (ja) | 2002-01-15 |
| HRP20000493A2 (en) | 2001-06-30 |
| NO20003765D0 (no) | 2000-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR014456A1 (es) | Derivados de sulfonamida como inhibidores de la resorcion osea y como inhibidores de la adhesion celular, un proceso para su preparacion ycomposicion farmaceutica que los contienen | |
| AR016437A1 (es) | Derivados de acilguanidina como inhibidores de resorcion osea y como antagonistas del receptor vitronectina, procedimiento para su preparacion ypreparacion farmaceutica que los comprenden | |
| AR018358A1 (es) | Acilguanidinas tienil-sustituidas como inhibidores de la resorcion de los huesos y como antagonistas de los receptores de la vitronectina, un proceso parasu preparacion y composicion farmaceutica que las comprende | |
| ES2097859T3 (es) | Derivados de dihidropiridina, su preparacion y su utilizacion. | |
| ES2075082T3 (es) | Derivados de isoquinolina para el tratamiento del glaucoma o hipertension ocular. | |
| AR011174A1 (es) | Compuestos de pirazina, composiciones farmaceuticas que los contienen, su uso en la peparacion de medicamentos y proceso para prepararlos | |
| CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
| PE20252237A1 (es) | Inhibidores macrociclicos de kras y metodos de uso | |
| AR023703A1 (es) | N-carboniloximetilesteres de nitroetilendiaminas y nitroguanidinas, proceso para su preparacion, composicion parasiticida, una preparacion en combinacionpara controlar parasitos en animales de sangre caliente, uso de dichos compuestos y compuestos intermediarios para su uso en dicho proceso de prepa | |
| AR082231A2 (es) | Piridinas y piridazinas sustituidas con actividad de inhibicion de angiogenesis, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento | |
| AR045938A1 (es) | Peptidos macrociclicos activos contra el virus de la hepatitis c | |
| AR029301A1 (es) | Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos | |
| ES2083438T3 (es) | Procedimiento para la preparacion de taxol utilizando una oxazinona. | |
| PE20080704A1 (es) | Inhibidores ns5b del virus hepatitis c de indolobenzazepina fusionados a ciclopropilo | |
| AR051698A1 (es) | Derivados de pirrolo[3,2-d]pirimidin-4-ona como inhibidores de mieloperoxidasa | |
| AR022848A1 (es) | Compuestos de imidazol sustituido con un anillo heterociclico de seis o siete miembros que contiene dos atomos de nitrogeno | |
| AR039189A1 (es) | Compuesto de pirrolopiridazina, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
| ES8602741A1 (es) | Un procedimiento para la preparacion de derivados de fenoxi-c3-c7-alquiloxi-3,4-dihidro-2h-1-benzopirano | |
| PE20011066A1 (es) | PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS | |
| ES2059335T3 (es) | Derivados de pirido(3,2,1-ij)-1,3,4-benzoxadiazina, procedimiento para su obtencion, preparados farmaceuticos correspondientes y productos intermedios utilizables en el procedimiento. | |
| PE20211703A1 (es) | Compuesto derivado heterotriciclico novedoso y uso del mismo | |
| MX23949A (es) | Compuestos diaza, y procedimiento para su preparaion y compociciones farmaceuticas anti-hipertesivay para el tratamiento de enfermedades cardiacas que los incluye. | |
| ES2072108T3 (es) | Procedimiento de tincion de fibras queratinicas que asocia isatina o uno de sus derivados a una aminopiridina o aminopirimidina, y agentes de tincion. | |
| CO5590916A2 (es) | Dicetopiperacinas sustituidas como antagonistas de oxitocina | |
| AR030203A1 (es) | Derivados de carbamato de 2-(s)-hidroximutilina, composiciones farmaceuticas que los comprenden, procedimiento para prepararlos y 2(s), 11-dihidroxi protegida-mutilina como compuesto intermediario |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |